Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $271000.0.

  • Lineage Cell Therapeutics' Change in Accured Expenses rose 15084.43% to $271000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$91000.0, marking a year-over-year increase of 8525.12%. This contributed to the annual value of -$1.7 million for FY2024, which is 2675.38% up from last year.
  • Lineage Cell Therapeutics' Change in Accured Expenses amounted to $271000.0 in Q3 2025, which was up 15084.43% from -$354000.0 recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Change in Accured Expenses ranged from a high of $21.3 million in Q4 2021 and a low of -$18.9 million during Q1 2022
  • Moreover, its 5-year median value for Change in Accured Expenses was -$325000.0 (2022), whereas its average is -$64263.2.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Change in Accured Expenses soared by 215909.09% in 2021 and then plummeted by 173365.66% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Change in Accured Expenses (Quarter) stood at $21.3 million in 2021, then plummeted by 105.3% to -$1.1 million in 2022, then soared by 202.83% to $1.2 million in 2023, then plummeted by 91.65% to $97000.0 in 2024, then soared by 179.38% to $271000.0 in 2025.
  • Its Change in Accured Expenses stands at $271000.0 for Q3 2025, versus -$354000.0 for Q2 2025 and -$105000.0 for Q1 2025.